Related Experiment Video

Updated: Aug 9, 2026

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer
07:13

Initiation of Metastatic Breast Carcinoma by Targeting of the Ductal Epithelium with Adenovirus-Cre: A Novel Transgenic Mouse Model of Breast Cancer

Published on: March 27, 2014

[Expression and activation of MAPK pathway signaling molecules in human breast cancer cell lines]

Qing Yao1, Jun-Rong Luo, Jiang-Hao Chen

  • 1Department of Vascular and Endocrine Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China. huanhuan@fmmu.edu.cn

Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi = Chinese Journal of Cellular and Molecular Immunology
|June 15, 2004
PubMed
Abstract

Insights

Overexpression of MEK and ERK proteins is linked to breast cancer development. Chemotherapy drugs cyclophosphamide and epirubicin inhibit cancer cell growth by reducing MEK and ERK signaling.

Area of Science:

  • Molecular Biology
  • Oncology
  • Cell Signaling

Background:

  • Extracellular signal-regulated kinases (ERK1/2) and their upstream activators (MEK1/2) are key regulators of cell proliferation.
  • Aberrant activation of the MEK/ERK pathway is implicated in various cancers, including breast cancer.

Purpose of the Study:

  • To investigate the expression and phosphorylation status of MEK1/2 and ERK1/2 in human breast cancer cell lines.
  • To evaluate the impact of cyclophosphamide and epirubicin on breast cancer cell proliferation and MEK/ERK signaling.

Main Methods:

  • Western blot analysis was employed to assess protein expression and phosphorylation levels of MEK1/2 and ERK1/2.
  • MTT colorimetry was used to determine the effects of cyclophosphamide and epirubicin on cell proliferation.

Main Results:

  • Breast cancer cell lines (MCF-7, Bcap-37, SK-BR-3, T47D) exhibited elevated MEK1/2 and ERK1/2 expression and phosphorylation compared to normal cells (MCF-10).
  • Both cyclophosphamide and epirubicin demonstrated significant inhibition of breast cancer cell proliferation.
  • Treatment with these drugs led to a marked decrease in MEK1/2 and ERK1/2 expression and phosphorylation in the treated cell lines.

Conclusions:

  • Overexpression and hyperphosphorylation of MEK and ERK are potentially crucial in the pathogenesis of human breast cancer.
  • Cyclophosphamide and epirubicin may exert their anti-proliferative effects on breast cancer cells by downregulating the MEK/ERK signaling pathway.

More Related Videos

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells06:54

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...